ZURA BIO
Zura Bio offers therapies for patients by incorporating immunology resources into phase 2 development programs, such as ZB-168 and torudokimab, with auto-immune illnesses. ZB-168 is an anti-IL7R inhibitor that may have an effect on disorders whose biological pathways are IL7 and TSLP. They create therapeutic indications for ZB-168 that build on the type 1 diabetes data from Phase 1b studies and show a profile and biological basis. The phase 2 clinical development stage of torudokimab, a human-affinity monoclonal antibody that neutralizes IL33, has been established.
ZURA BIO
Social Links:
Industry:
Biopharma Biotechnology Medical
Founded:
2022-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.zurabio.com
Total Employee:
11+
Status:
Active
Contact:
1-858-247-0520
Email Addresses:
[email protected]
Total Funding:
192.5 M USD
Technology used in webpage:
Euro Content Delivery Network HSTS JsDelivr CrUX Dataset BootstrapCDN JQuery CDN CrUX Top 10m COVID-19 OVH
Similar Organizations
Alios BioPharma
Alios BioPharma is a biotechnology company developing novel medicines for the treatment of viral diseases.
Ansun BioPharma
Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of host-directed anti-viral.
Clementia Pharmaceuticals
Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders.
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
Sitari Pharmaceuticals
Sitari Pharmaceuticals is a biotechnology company developing treatments for multiple disease indications.
Symvivo Corporation
Symvivo Corporation is a clinical-stage biotechnology company that develops DNA vaccines for genetic and life-threatening diseases.
Trestle Biotherapeutics
Trestle Biotherapeutics is a biotechnology company that introduces bioengineered kidneys for patients with kidney disease.
Zylem Biosciences
Zylem Biosciences is a startup biotechnology company developing targeted medicines that uniquely mimic features of natural biologics.
Current Advisors List
Current Employees Featured
Stock Details
Investors List
Allostery Investments
Allostery Investments investment in Post-IPO Equity - Zura Bio
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Zura Bio
Deep Track Capital
Deep Track Capital investment in Post-IPO Equity - Zura Bio
Great Point Partners
Great Point Partners investment in Post-IPO Equity - Zura Bio
Armistice Capital
Armistice Capital investment in Post-IPO Equity - Zura Bio
Access Biotechnology
Access Biotechnology investment in Post-IPO Equity - Zura Bio
Suvretta Capital Management
Suvretta Capital Management investment in Post-IPO Equity - Zura Bio
Great Point Partners
Great Point Partners investment in Post-IPO Equity - Zura Bio
Suvretta Capital Management
Suvretta Capital Management investment in Post-IPO Equity - Zura Bio
Deep Track Capital
Deep Track Capital investment in Post-IPO Equity - Zura Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2024-04-08 | Zura Bio Announces Robert Lisicki as CEO and Director |
| 2024-03-28 | Zura Bio names Robert Lisicki as CEO, succeeding Someit Sidhu, M.D. |
| 2023-04-14 | Zura Bio Announces Appointment of Chief Scientific Officer |
Official Site Inspections
http://www.zurabio.com Semrush global rank: 4.23 M Semrush visits lastest month: 2.35 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Zura Bio"
About Us - Zura Bio
Our team, composed of industry experts and asset-hunters, leverages a dual antagonism strategy to target multiple mechanisms or pathways simultaneously, thereby potentially increasing the …See details»
Zura Bio - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 1-858-247-0520 Zura Bio offers therapies for patients by incorporating immunology resources into phase 2 …See details»
SEC Filing | Zura Bio Ltd - investors.zurabio.com
Sep 3, 2024 organization) 2834 (Primary Standard Industrial Classification Code Number) 98-172573 (I.R.S. Employer Identification Number) 1489 W. Warm Springs Rd. #110 ... We also …See details»
Zura Bio Limited (Nasdaq: ZURA) | LinkedIn
Zura Bio is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Currently, Zura Bio is developing three assets which ...See details»
Zura Bio Limited (ZURA) Company Profile & Facts - Yahoo
See the company profile for Zura Bio Limited (ZURA) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
Investor Relations | Zura Bio Ltd
Dec 23, 2024 The Investor Relations website contains information about Zura Bio Ltd's business for stockholders, potential investors, and financial analysts.See details»
Patients | Zura Bio
If you are a physician interested in learning more about our investigational therapies, please contact us at [email protected]. CONTACT US. 1489 W. Warm Springs Road Suite 110 …See details»
Zura Bio - The Org
Zura Bio is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Currently, Zura Bio is developing three …See details»
Zura Bio Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Zurabio.com. Public Company | 2022 | California, United States | 10-50 | NASDAQ: ZURA | zurabio.com. Last update 08 Mar 2025. Overview. Pipeline. Deal. Translational Medicine. ...See details»
Zura Bio Reports Third Quarter 2024 Financial Results and Recent ...
Nov 7, 2024 "In the third quarter of 2024, we made significant progress toward initiating our first Phase 2 trial of tibulizumab in SSc. We’ve worked closely with our contract research …See details»
Zura Bio - Leadership Team - The Org
The Leadership Team at Zura Bio Limited (Nasdaq: ZURA) is responsible for guiding the strategic direction of the company, ensuring the successful development of its clinical-stage assets for …See details»
Zura Bio Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Zura Bio is company a clinical-stage biotechnology company advancing immunology assets into development programs. It aims to develop a portfolio of therapeutic …See details»
Zura Bio - Products, Competitors, Financials, Employees, …
Headquarters Location. 4225 Executive Square Suite 600. San Diego, California, 92037, United States. 858-247-0520See details»
Zura Bio - VentureRadar
Similar Companies: Biotheus China Private Founded in April 2018, we are a biotech startup focusing on the discovery and development of next generation antibody-based therapeutics. …See details»
Release Details - investors.zurabio.com
Dec 31, 2024 In September 2024, a third-party Contract Research Organization was selected to oversee and conduct the Phase 2 clinical program for HS. Zura Bio holds an active …See details»
Zura Bio Reports Full Year 2024 Financial Results and Recent …
5 days ago HENDERSON, Nev., March 25, 2025--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"), a clinical stage, multi-asset immunology company developing novel dual …See details»
Pipeline - Zura Bio
Zura Bio is focused on the development of therapies in challenging immunological conditions by deeply interrogating the therapeutic mechanism of action and pairing that with those patients …See details»
Zura Bio Reports Full Year 2024 Financial Results and Recent
4 days ago Achieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipeline Initiated the Phase 2 TibuSURE trial …See details»
Zura Bio - VentureRadar
Dansk Biotek Unknown n/a DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and …See details»
Release Details - investors.zurabio.com
"Single-pathway inhibition has demonstrated modest effects in rheumatic diseases like SSc. This is why we believe tibulizumab's dual-pathway approach holds the potential to be best-in-class, …See details»